197 related articles for article (PubMed ID: 18624685)
1. Experience with exemestane in the treatment of early and advanced breast cancer.
Lønning PE; Geisler J
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):987-97. PubMed ID: 18624685
[TBL] [Abstract][Full Text] [Related]
2. Drug safety evaluation of exemestane.
Lintermans A; Neven P; Paridaens R
Expert Opin Drug Saf; 2011 May; 10(3):473-87. PubMed ID: 21428848
[TBL] [Abstract][Full Text] [Related]
3. Exemestane in postmenopausal women with early or advanced breast cancer: a review.
Bertelli G; Gangadhara S
Expert Opin Pharmacother; 2010 Aug; 11(11):1933-42. PubMed ID: 20569090
[TBL] [Abstract][Full Text] [Related]
4. Exemestane: a review of its use in postmenopausal women with breast cancer.
Deeks ED; Scott LJ
Drugs; 2009; 69(7):889-918. PubMed ID: 19441873
[TBL] [Abstract][Full Text] [Related]
5. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Buzdar AU; Robertson JF; Eiermann W; Nabholtz JM
Cancer; 2002 Nov; 95(9):2006-16. PubMed ID: 12404296
[TBL] [Abstract][Full Text] [Related]
6. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
7. The role of aromasin in the hormonal therapy of breast cancer.
Dank M
Pathol Oncol Res; 2002; 8(2):87-92. PubMed ID: 12172571
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology and clinical experience with exemestane.
Lønning PE
Expert Opin Investig Drugs; 2000 Aug; 9(8):1897-905. PubMed ID: 11060785
[TBL] [Abstract][Full Text] [Related]
9. Exemestane: a milestone against breast cancer.
Shetty YC; Chakkarwar PN; Acharya SS; Rajadhyaksha VD
J Postgrad Med; 2007; 53(2):135-8. PubMed ID: 17495383
[TBL] [Abstract][Full Text] [Related]
10. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2-3 years treatment with tamoxifen in Sweden.
Lundkvist J; Wilking N; Holmberg S; Jönsson L
Breast Cancer Res Treat; 2007 May; 102(3):289-99. PubMed ID: 17033927
[TBL] [Abstract][Full Text] [Related]
12. Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment.
Dixon JM
Expert Rev Anticancer Ther; 2002 Jun; 2(3):267-75. PubMed ID: 12113050
[TBL] [Abstract][Full Text] [Related]
13. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
Bertelli G; Garrone O; Merlano M; Occelli M; Bertolotti L; Castiglione F; Pepi F; Fusco O; Del Mastro L; Leonard RC
Oncology; 2005; 69(6):471-7. PubMed ID: 16410685
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
Risebrough NA; Verma S; Trudeau M; Mittmann N
Cancer; 2007 Aug; 110(3):499-508. PubMed ID: 17592825
[TBL] [Abstract][Full Text] [Related]
15. The role of aromatase inactivators in the treatment of breast cancer.
Lønning PE
Int J Clin Oncol; 2002 Aug; 7(4):265-70. PubMed ID: 12202980
[TBL] [Abstract][Full Text] [Related]
16. Aromatase inhibitors in the breast cancer clinic: focus on exemestane.
Van Asten K; Neven P; Lintermans A; Wildiers H; Paridaens R
Endocr Relat Cancer; 2014 Feb; 21(1):R31-49. PubMed ID: 24434719
[TBL] [Abstract][Full Text] [Related]
17. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Clemett D; Lamb HM
Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
[TBL] [Abstract][Full Text] [Related]
18. Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Mouridsen HT; Robert NJ
MedGenMed; 2005 Aug; 7(3):20. PubMed ID: 16369246
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitors in advanced breast cancer.
Mouridsen HT
Semin Oncol; 2004 Dec; 31(6 Suppl 12):3-8. PubMed ID: 15719595
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
